PDCD1 and ovarian cancer: They evaluated the programmed cell death protein 1 (PD-1) blockade response of 37 tumors from five cancer types (i.e., melanoma, non-small-cell lung cancer, breast cancer, ovarian cancer, and renal cell carcinoma) on this platform.